Fig. 1

Effect of vistusertib alone or in combination with endocrine agents in several cell line models of endocrine sensitivity and resistance BC. a–c Effect of escalating doses of vistusertib on proliferation of a MCF7, b MCF7 LTED^Y537C and c MCF7 LTED^wt cell lines in the absence and in the presence of 0.01 nM E2. d, e Effect of escalating doses of vistusertib on proliferation of d tamoxifen (MCF7 TAMR)- and e fulvestrant (MCF7 ICIR and MCF7 LTED ICIR)-resistant cell lines. f, g Effect of escalating doses of fulvestrant in the presence or in the absence of 75 nM of vistusertib on both f MCF7 LTED^wt and g MCF7 LTED^Y537C (left panels) and respective combination index heatmaps (right panels). Data are expressed as luminescence relative to vehicle control. Cell viability was analysed using a CellTiter-Glo assay. Error bars represent mean ± SEM